Business Description
Alembic Pharmaceuticals Ltd
ISIN : INE901L01018
Total Employee Number:
16,571Compare
Compare
Traded in other countries / regions
533573.India IPO Date
2011-09-20Description
Alembic Pharmaceuticals Ltd is a vertically integrated pharmaceutical company engaged in the pharmaceuticals business. Its products are broadly classified into Active Pharmaceutical Ingredients (APIs), Formulations and International Generics, serving a large international and national customer base across various geographies. Its manufacturing infrastructure is equipped to serve the full spectrum of complex and specialty pharmaceutical segments spanning drug delivery formats, oncology, injectables, ophthalmics and dermatology. Customers include pharmaceutical companies engaged in the formulation business, patients, healthcare facilities and pharmaceutical distributors.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.14 | |||||
Equity-to-Asset | 0.65 | |||||
Debt-to-Equity | 0.25 | |||||
Debt-to-EBITDA | 1.29 | |||||
Interest Coverage | 8.54 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 5.21 | |||||
Beneish M-Score | -2.01 | |||||
WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 9.5 | |||||
3-Year EBITDA Growth Rate | 17.6 | |||||
3-Year EPS without NRI Growth Rate | 28.8 | |||||
3-Year FCF Growth Rate | 0.9 | |||||
3-Year Book Growth Rate | 9.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 19.02 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 30.9 | |||||
9-Day RSI | 41.13 | |||||
14-Day RSI | 46.93 | |||||
3-1 Month Momentum % | 3.93 | |||||
6-1 Month Momentum % | 2.37 | |||||
12-1 Month Momentum % | -23.34 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.75 | |||||
Quick Ratio | 0.78 | |||||
Cash Ratio | 0.08 | |||||
Days Inventory | 449.98 | |||||
Days Sales Outstanding | 69.24 | |||||
Days Payable | 159.55 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 1.38 | |||||
Dividend Payout Ratio | 0.3 | |||||
3-Year Dividend Growth Rate | 3.2 | |||||
Forward Dividend Yield % | 1.51 | |||||
5-Year Yield-on-Cost % | 1.39 | |||||
Shareholder Yield % | -0.52 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 72.98 | |||||
Operating Margin % | 10.89 | |||||
Net Margin % | 9.19 | |||||
EBITDA Margin % | 15.06 | |||||
FCF Margin % | 3.92 | |||||
OCF Margin % | 10.66 | |||||
ROE % | 12.51 | |||||
ROA % | 8.12 | |||||
ROIC % | 10.87 | |||||
3-Year ROIIC % | 16.04 | |||||
ROC (Joel Greenblatt) % | 12.38 | |||||
ROCE % | 13.74 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 23.21 | |||||
Forward PE Ratio | 20.98 | |||||
PE Ratio without NRI | 21.63 | |||||
Shiller PE Ratio | 20.18 | |||||
Price-to-Owner-Earnings | 32.23 | |||||
PS Ratio | 2.13 | |||||
PB Ratio | 2.76 | |||||
Price-to-Tangible-Book | 2.91 | |||||
Price-to-Free-Cash-Flow | 54.39 | |||||
Price-to-Operating-Cash-Flow | 20 | |||||
EV-to-EBIT | 21.44 | |||||
EV-to-EBITDA | 15.26 | |||||
EV-to-Revenue | 2.3 | |||||
EV-to-FCF | 58.66 | |||||
Price-to-GF-Value | 0.76 | |||||
Price-to-Projected-FCF | 2.53 | |||||
Price-to-Median-PS-Value | 0.71 | |||||
Price-to-Graham-Number | 1.65 | |||||
| Price-to-Net-Current-Asset-Value | 10.76 | |||||
Earnings Yield (Greenblatt) % | 4.66 | |||||
FCF Yield % | 1.84 | |||||
Forward Rate of Return (Yacktman) % | -1.39 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Alembic Pharmaceuticals Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 73,449 | ||
| EPS (TTM) (₹) | 34.32 | ||
| Beta | 1.4571 | ||
| 3-Year Sharpe Ratio | 0.23 | ||
| 3-Year Sortino Ratio | 0.44 | ||
| Volatility % | 25.8 | ||
| 14-Day RSI | 46.93 | ||
| 14-Day ATR (₹) | 22.864156 | ||
| 20-Day SMA (₹) | 822.6475 | ||
| 12-1 Month Momentum % | -23.34 | ||
| 52-Week Range (₹) | 635.3 - 1026.95 | ||
| Shares Outstanding (Mil) | 196.56 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Alembic Pharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Alembic Pharmaceuticals Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| INR 12.000000 Cash Dividend | 2026-07-29 | In 3 days | ||
| INR 11.000000 Cash Dividend | 2025-07-29 | 1,003.75 (+0.56%) |
Show
Entries
Alembic Pharmaceuticals Ltd Frequently Asked Questions
What is Alembic Pharmaceuticals Ltd(BOM:533573)'s stock price today?
The current price of BOM:533573 is ₹796.50. The 52 week high of BOM:533573 is ₹1026.95 and 52 week low is ₹635.30.
When is next earnings date of Alembic Pharmaceuticals Ltd(BOM:533573)?
The next earnings date of Alembic Pharmaceuticals Ltd(BOM:533573) is .
Does Alembic Pharmaceuticals Ltd(BOM:533573) pay dividends? If so, how much?
The Dividend Yield %  of Alembic Pharmaceuticals Ltd(BOM:533573) is 1.38% (As of Today), Highest Dividend Payout Ratio of Alembic Pharmaceuticals Ltd(BOM:533573) was 0.57. The lowest was 0.13. And the median was 0.28. The  Forward Dividend Yield % of Alembic Pharmaceuticals Ltd(BOM:533573) is 1.51%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Alembic Pharmaceuticals Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers